Black Rock Inc. Neoleukin Therapeutics, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.68 - $0.91 $54,758 - $73,279	-80,527 Reduced 14.27%	483,948 $401,000
Q1 2023 May 12, 2023	SELL	$0.5 - $0.72 $24,733 - $35,616	-49,467 Reduced 8.06%	564,475 $395,000
Q4 2022 Feb 13, 2023	SELL	$0.4 - $0.55 $110,142 - $151,445	-275,356 Reduced 30.96%	613,942 $313,000
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.33 $14,858 - $28,640	-21,534 Reduced 2.36%	889,298 $569,000
Q2 2022 Aug 12, 2022	SELL	$0.92 - $2.25 $1.52 Million - $3.71 Million	-1,647,647 Reduced 64.4%	910,832 $938,000
Q1 2022 May 12, 2022	SELL	$1.72 - $5.23 $79,405 - $241,448	-46,166 Reduced 1.77%	2,558,479 $4.81 Million
Q4 2021 Feb 10, 2022	SELL	$4.65 - $7.75 $300,534 - $500,890	-64,631 Reduced 2.42%	2,604,645 $12.6 Million
Q3 2021 Nov 09, 2021	BUY	$6.05 - $9.66 $184,633 - $294,803	30,518 Added 1.16%	2,669,276 $19.3 Million
Q2 2021 Aug 11, 2021	BUY	$9.23 - $13.12 $24.4 Million - $34.6 Million	2,638,758 New	2,638,758 $24.4 Million

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.